SCHEMBL661197

SCHEMBL661197

CC(=O)c1ccc(O)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.55
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
HSD17B10 Q99714 1/20 0.53
SNCA P37840 1/20 0.53
ESR1 P03372 3/20 0.51
ESR2 Q92731 3/20 0.51
HTT P42858 1/20 0.49
POLB P06746 1/20 0.47
ACHE P22303 1/20 0.46
HSD17B1 P14061 3/20 0.46
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
CYP17A1 P05093 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP19A1 P11511 1/20 0.44
CYP11B1 P15538 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9150363 0.84 KDM4E (0.71) PKMKDM4ELMNAHSD17B10ESR1
SCHEMBL29818197 0.83 HSD17B14 (0.53) PKMHTTHSD17B1CES2CES1
SCHEMBL658959 0.83 HSD17B14 (0.53) PKMHTTHSD17B1CES2CES1
SCHEMBL27661242 0.82 HSD17B1 (0.59) KDM4ELMNAHSD17B10SNCAESR1
SCHEMBL29748711 0.82 HSD17B1 (0.59) KDM4ELMNAHSD17B10SNCAESR1
SCHEMBL29669896 0.82 CES2 (0.67) PKMCES2CES1NPC1MAPT
SCHEMBL75801 0.82 CES2 (0.67) PKMCES2CES1NPC1MAPT
SCHEMBL30574898 0.80 KDM4E (0.71) KDM4ELMNAHSD17B10SNCAESR1
SCHEMBL226720 0.80 KDM4E (0.71) KDM4ELMNAHSD17B10SNCAESR1
SCHEMBL144106 0.79 CA12 (0.62) PKMKDM4ESNCAHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120081885-A Substituted phenyl glycoside compound and preparation method and application thereof 浙江大学 2025-06-03 CN claimed
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 US disclosed
EP-4665458-A1 INHIBITING ALPHA V BETA8 INTEGRIN Morphic Therapeutic, Inc. (US) 2025-12-24 EP disclosed
EP-4665339-A1 INHIBITING ALPHA V BETA 8 INTEGRIN Morphic Therapeutic, Inc. (US) 2025-12-24 EP disclosed
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 EP disclosed
US-12378256-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-08-05 US disclosed
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
CN-120081885-A Substituted phenyl glycoside compound and preparation method and application thereof 浙江大学 2025-06-03 CN disclosed
EP-0341686-B1 Novel halogen-containing ester compounds, and their intermediates, and method of producing the same as well as liquid crystal compositions containing the same and light switching elements JAPAN ENERGY CORP (JP) 1994-08-17 EP disclosed
EP-0589018-A1 AMINES AS INHIBITORS OF SQUALENE SYNTHASE ZENECA LIMITED (GB) 1994-03-30 EP disclosed
WO-1993020807-A1 AMINES AS INHIBITORS OF SQUALENE SYNTHASE ZENECA LIMITED (GB) 1993-10-28 WO disclosed
US-5098602-A Aromatic ester derivatives and fluorophenol ketones NIPPON MINING CO., LTD. (JP) 1992-03-24 US disclosed
US-5026729-A Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1991-06-25 US disclosed
EP-0341686-A2 Novel halogen-containing ester compounds, and their intermediates, and method of producing the same as well as liquid crystal compositions containing the same and light switching elements JAPAN ENERGY CORPORATION (JP) 1989-11-15 EP disclosed
US-4649160-A HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS HOFFMANN-LA ROCHE INC. (US) 1987-03-10 US disclosed
EP-0041233-B1 SUBSTITUTED PHENOXY-AMINOPROPANOL DERIVATIVES, INTERMEDIATES AND PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-02-15 EP disclosed
EP-0041233-A1 Substituted phenoxy-aminopropanol derivatives, intermediates and processes for their production, and pharmaceutical preparations containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-12-09 EP disclosed
US-4190671-A ANTIINFLAMMATORY, ANTIALLERGENIC, ANTIULCER BIOREX LABORATORIES LIMITED (GB) 1980-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378256-B2 Heterocyclic compound SLC10A2, ALPI, VIP PKM 2777/4885KDM4E 1923/4885LMNA 4125/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK PKM 1364/4885KDM4E 2066/4885LMNA 3162/4885
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A PKM 4721/4885KDM4E 3880/4885LMNA 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.